XA+ NHL is a fictional subtype of a real disease. All content shown here, including claims, data and references, is fictional and intended to represent a hypothetical clinical scenario.

Natevba® (vevasumab):
Precision targeting in XA+
non-Hodgkin’s lymphoma

Introducing Natevba®

  • Natevba® is an innovative new treatment targeting X-antigen1
  • Natevba® is indicated for the first-line treatment of X-antigen positive (XA+) non-Hodgkin’s lymphoma1
packge of medicine

Natevba® is the only treatment to target X-antigen, a highly specific marker of malignant lymphocytes1

Watch the video below to see Natevba® in action.

Play button